Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension

B Nazer, BD Humphreys, J Moslehi - Circulation, 2011 - Am Heart Assoc
Circulation, 2011Am Heart Assoc
1687 target other tyrosine kinase receptors. For example, sunitinib and sorafenib, the first
receptor tyrosine kinase inhibitors with potent anti-VEGFR inhibition, also target platelet-
derived growth factor receptor, as well as c-kit (receptor for stem cell factor). The multiple
receptor tyrosine kinase targets of these drugs have implications both for their therapeutic
potency and for their cardiotoxicities.
1687 target other tyrosine kinase receptors. For example, sunitinib and sorafenib, the first receptor tyrosine kinase inhibitors with potent anti-VEGFR inhibition, also target platelet-derived growth factor receptor, as well as c-kit (receptor for stem cell factor). The multiple receptor tyrosine kinase targets of these drugs have implications both for their therapeutic potency and for their cardiotoxicities.
Am Heart Assoc